Table 3.
Patient characteristics improved pharmacokinetic model
| Model building cohort (n = 95) | |
|---|---|
| Recipient sex, n (%) | |
| Male | 58 (61) |
| Age of recipient (years) | 11.4 (1.6–17.9) |
| Ethnicity, n (%) | |
|
Caucasian Asian African descent Other |
71 (74) 2 (2) 9 (9) 13 (14) |
| Bodyweight (kg)a | 32.0 (10.4–87.5) |
| Height (cm)a | 138 (73–188) |
| Laboratory measurements | |
| Hematocrit (L/L) | 0.29 (0.16–0.52) |
| Creatinine (µmol/L) | 84 (12–1454) |
| eGFR (mL/min) [28] | 63 (2.9–274) |
| ASAT (U/L) | 29 (7–217) |
| Albumin (g/L) | 34 (11–52) |
| CRP (mg/L) | 6.4 (0.3–268) |
| Total protein (g/L) | 61 (34–80) |
| CYP3A4, n (%) | |
| *1/*1 | 34 (36) |
| *1/*1G | 8 (8) |
| *1G/*1G | 3 (3) |
| *22 | 2 (2) |
| Unknown | 48 (51) |
| CYP3A5, n (%) | |
| *1/*1 | 3 (3) |
| *1/*3 | 11 (12) |
| *3/*3 | 52 (55) |
| *3/*7 | 2 (2) |
| Unknown | 27 (28) |
| Primary diagnosis, n (%) | |
| CAKUT | 46 (48) |
| Glomerular kidney disease | 22 (23) |
| Cystic kidney disease/nephronophthisis | 12 (13) |
| Other/unknown | 15 (16) |
| Number of kidney transplantations, n (%) | |
| First | 90 (95) |
| Second | 5 (5) |
| RRT prior to kidney transplantation, n (%) | |
| Hemodialysis | 28 (29) |
| Peritoneal dialysis | 23 (24) |
| Pre-emptive | 44 (46) |
| Donor type, n (%) | |
| Living | 74 (78) |
| Deceased | 21 (22) |
| Route of administration, n (%) | |
| Suspension | 24 (25) |
| Capsule | 89 (94) |
| Co-medication, n (%) | |
| Calcium channel blockers | |
| Amlodipine | 51 (54) |
| Nifedipine | 23 (24) |
| Antibiotics | |
| Erythromycin | 1 (1) |
| Antimycotics | |
| Fluconazole | 2 (2) |
| Voriconazole | 1 (1) |
| Distribution of tacrolimus samples | |
| Total samples | 1338 |
| 0–7 days post-transplantation | 286 (21) |
| 8–14 days post-transplantation | 515 (38) |
| 15–21 days post-transplantation | 218 (16) |
| 22–42 days post-transplantation | 319 (24) |
| Tacrolimus analysis | |
| Immunoassay | 64 (4.8) |
| LC–MS/MS | 1274 (95.2) |
ASAT aspartate aminotransferase, C0 pre-dose concentration, CAKUT congenital anomalies of the kidney and the urinary tract, CYP cytochrome P450, eGFR estimated glomerular filtration rate, LC–MS/MS liquid chromatography–tandem mass spectrometry, RRT renal replacement therapy
aPresented as median and range for continuous variables